索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]张浩天,张瑞岩.糖尿病冠心病患者支架置入后内膜修复研究现状[J].国际心血管病杂志,2017,04:193-195.
点击复制

糖尿病冠心病患者支架置入后内膜修复研究现状(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2017年04期
页码:
193-195
栏目:
综述
出版日期:
2017-07-25

文章信息/Info

Title:
-
作者:
张浩天; 张瑞岩
200025 上海交通大学医学院附属瑞金医院心脏科
Author(s):
-
关键词:
糖尿病; 冠状动脉粥样硬化性心脏病; 药物洗脱支架; 内膜修复; 光学相干断层扫描
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2017.04.001
文献标识码:
-
摘要:
糖尿病冠状动脉粥样硬化性心脏病患者冠状动脉支架置入后临床预后不良,支架内再狭窄及支架内血栓发生率较非糖尿病患者升高。该文介绍利用光学相干断层扫描成像方法评估糖尿病患者冠状动脉支架置入后内膜增生与愈合不良的原因及对临床预后的影响。
Abstract:
-

参考文献/References

[1] 刘慧竹, 张瑞岩. 影响药物洗脱支架置入术后新生内膜生成的因素[J]. 国际心血管病杂志, 2015, 42(5):316-319.
[2] 张文俐, 张瑞岩. 光学相干断层扫描评价糖尿病冠心病患者冠脉病变的进展[J]. 国际心血管病杂志, 2014, 41(5):327-330.
[3] Tian F, Chen YD, Liu HB, et al. Assessment of characteristics of neointimal hyperplasia after drug-eluting stent implantation in patients with diabetes mellitus: an optical coherence tomography analysis[J]. Cardiology, 2014, 128(1):34-40.
[4] Goto K, Zhao Z, Matsumura M, et al. Mechanisms and patterns of intravascular ultrasound in-stent restenosis among bare metal stents and first- and second-generation drug-eluting stents[J]. Am J Cardiol, 2015, 116(9):1351-1357.
[5] Tanaka N, Terashima M, Rathore S, et al. Different patterns of vascular response between patients with or without diabetes mellitus after drug-eluting stent implantation optical coherence tomographic analysis[J]. JACC Cardiovasc Interv, 2010, 3(10):1074-1079.
[6] Iwasaki M, Otake H, Shinke T, et al. Vascular responses in patients with and without diabetes mellitus after everolimus-eluting stent implantation[J]. Circ J, 2014, 78(9):2188-2196.
[7] Taruya A, Tanaka A, Nishiguchi T, et al. Vasa vasorum restructuring in human atherosclerotic plaque vulnerability a clinical optical coherence tomography study[J]. J Am Coll Cardiol, 2015, 65(23):2469-2477.
[8] Suzuki N, Kozuma K, Kyono H, et al. Predominant microvessel proliferation in coronary stent restenotic tissue in patients with diabetes: insights from optical coherence tomography image analysis[J]. Int J Cardiol, 2013, 168(2):843-847.
[9] Gao L, Park SJ, Jang Y, et al. Comparison of neoatherosclerosis and neovascularization between patients with and without diabetes an optical coherence tomography study[J]. JACC Cardiovasc Interv, 2015, 8(8):1044-1052.
[10] Ozaki Y, Okumura M, Ismail TF, et al. The fate of incomplete stent apposition with drug-eluting stents: an optical coherence tomography-based natural history study[J]. Eur Heart J, 2010, 31(12):1470-1476.
[11] Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization[J]. Circulation, 2007, 115(18):2435-2441.
[12] Nagai H, Ishibashi-Ueda H, Fujii K. Histology of highly echolucent regions in optical coherence tomography images from two patients with sirolimus-eluting stent restenosis[J]. Catheter Cardiovasc Interv, 2010, 75(6):961-963.
[13] Lee SY, Shin DH, Kim JS, et al. Optical coherence tomographic observation of morphological features of neointimal tissue after drug-eluting stent implantation[J]. Yonsei Med J, 2014, 55(4):944-952.
[14] Gonzalo N, Serruys PW, Okamura T, et al. Optical coherence tomography patterns of stent restenosis [J]. Am Heart J, 2009, 158(2):284-293.
[15] Otake H, Shite J, Ako J, et al. Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography[J]. JACC Cardiovasc Interv, 2009, 2(5):459-466.
[16] Yamawaki M, Terashita D, Takahashi H, et al. Impact of diabetes mellitus on intravascular ultrasound-guided provisional stenting in coronary bifurcation lesions J-REVERSE sub-study[J]. J Interv Cardiol, 2016, 29(6):576-587.
[17] Mak KH, Faxon DP. Clinical studies on coronary revascularization in patients with type 2 diabetes[J]. Eur Heart J, 2003, 24(12):1087-1103.
[18] Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty[J]. Circulation, 1995, 91(4): 979-989.
[19] De Luca G, Sauro R, Capasso M, et al. Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction[J]. Diab Vasc Dis Res, 2015, 12(5):306-314.
[20] Ritsinger V, Saleh N, Lagerqvist B, et al. High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus results from the Swedish coronary angiography and angioplasty registry[J]. Circ Cardiovasc Interv, 2015, 8(6):e002328.
[21] Bangalore S, Kumar S, Fusaro M, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials [J]. BMJ, 2012, 345:e5170.
[22] Kawecki D, Morawiec B, Dola J, et al. Comparison of first- and second-generation drug-eluting stents in an all-comer population of patients with diabetes mellitus(from Katowice-Zabrze registry)[J]. Med Sci Monit, 2015, 21:3261-3269.
[23] Parikh PP, Levy MS. Drug-eluting stents and diabetes: a generation gap?[J]. Catheter Cardiovasc Interv, 2013, 81(7):1115-1116.
[24] Ndrepepa G, King L, Kastrati A. More deserved focus on diabetic patients[J]. Circ Cardiovasc Interv, 2011, 4(2):115-117.
[25] Vardi M, Burke DA, Bangalore S, et al. Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR Ⅲ and Ⅳ trials[J]. Catheter Cardiovasc Interv, 2013, 82(7):1031-1038.
[26] Park KW, Lee JM, Kang SH, et al. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus[J]. JACC Cardiovasc Interv, 2014, 7(5):471-481.
[27] Saito S, Maehara A, Vlachojannis GJ, et al. Clinical and angiographic evaluation of the resolute zotarolimus-eluting coronary stent in Japanese patients—long-term outcome in the RESOLUTE Japan and RESOLUTE Japan small vessel study[J]. Circ J, 2015, 79(1):96-103.
[28] Lowik MM, Lam MK, Sen H, et al. Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial[J]. EuroIntervention, 2015, 10(11):1276-1279.
[29] Silber S, Serruys PW, Leon MB, et al. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent 2-year results from the prospectively pooled analysis of the international global RESOLUTE program[J]. JACC Cardiovasc Interv, 2013, 6(4):357-368.

备注/Memo

备注/Memo:
通信作者:张瑞岩,Email:zhangruiyan@263.net
更新日期/Last Update: 2017-07-25